Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.

Literature DB >> 27141357

Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.

Abstract

Human tumor-derived soluble NKG2D sMIC paralyzes the immune system through multiple pathways. Targeting soluble MIC with a nonblocking sMIC-neutralizing anti-MIC antibody effectuated and revamped endogenous innate and adoptive antitumor responses. Therapy induced regression of primary tumors and eliminated metastasis in preclinical models.

Entities: Disease Gene Species

Keywords: Cancer immunotherapy; NKG2D ligands; nonblocking sMIC-neutralizing anti-MIC antibody; soluble MIC

Year: 2015 PMID： 27141357 PMCID： PMC4839309 DOI： 10.1080/2162402X.2015.1095434

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

Review 1. Roles of the NKG2D immunoreceptor and its ligands.

Authors: David H Raulet
Journal: Nat Rev Immunol Date: 2003-10 Impact factor: 53.106

2. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

Authors: Masahisa Jinushi; F Stephen Hodi; Glenn Dranoff
Journal: Proc Natl Acad Sci U S A Date: 2006-06-05 Impact factor: 11.205

3. Distinct mechanisms of tumor resistance to NK killing: of mice and men.

Authors: Drew M Pardoll
Journal: Immunity Date: 2015-04-21 Impact factor: 31.745

4. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

Authors: Gang Liu; Shengjun Lu; Xuanjun Wang; Stephanie T Page; Celestia S Higano; Stephen R Plymate; Norman M Greenberg; Shaoli Sun; Zihai Li; Jennifer D Wu
Journal: J Clin Invest Date: 2013-09-09 Impact factor: 14.808

5. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

Authors: Weiwen Deng; Benjamin G Gowen; Li Zhang; Lin Wang; Stephanie Lau; Alexandre Iannello; Jianfeng Xu; Tihana L Rovis; Na Xiong; David H Raulet
Journal: Science Date: 2015-03-05 Impact factor: 47.728

6. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.

Authors: Shengjun Lu; Jinyu Zhang; Dai Liu; Guangfu Li; Kevin F Staveley-O'Carroll; Zihai Li; Jennifer D Wu
Journal: Clin Cancer Res Date: 2015-06-23 Impact factor: 12.531

Review 7. NKG2D ligands in tumor immunity.

Authors: N Nausch; A Cerwenka
Journal: Oncogene Date: 2008-10-06 Impact factor: 9.867

8. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.

Authors: Gang Xiao; Xuanjun Wang; Jun Sheng; Shengjun Lu; Xuezhong Yu; Jennifer D Wu
Journal: J Hematol Oncol Date: 2015-02-20 Impact factor: 17.388

Review 9. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin.

Authors: Jinyu Zhang; Fahmin Basher; Jennifer D Wu
Journal: Front Immunol Date: 2015-03-04 Impact factor: 7.561

Review 10. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.

Authors: Aroa Baragaño Raneros; Beatriz Suarez-Álvarez; Carlos López-Larrea
Journal: Oncoimmunology Date: 2014-04-25 Impact factor: 8.110

10 in total

1. Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.

Authors: Alejandro López-Soto; Segundo Gonzalez; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2017-07-13 Impact factor: 8.110

Review 2. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Authors: Claire Lhuillier; Claire Vanpouille-Box; Lorenzo Galluzzi; Silvia Chiara Formenti; Sandra Demaria
Journal: Semin Cancer Biol Date: 2017-12-16 Impact factor: 15.707

3. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Authors: Cristina Maccalli; Diana Giannarelli; Carla Chiarucci; Ornella Cutaia; Gianluca Giacobini; Wouter Hendrickx; Giovanni Amato; Diego Annesi; Davide Bedognetti; Maresa Altomonte; Riccardo Danielli; Luana Calabrò; Anna Maria Di Giacomo; Francesco M Marincola; Giorgio Parmiani; Michele Maio
Journal: Oncoimmunology Date: 2017-05-08 Impact factor: 8.110

10. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC⁺ tumors respond to PD1/PD-L1 blockade therapy.

Authors: Jinyu Zhang; Pablo Saenz-Lopez Larrocha; Bin Zhang; Derek Wainwright; Payal Dhar; Jennifer D Wu
Journal: J Immunother Cancer Date: 2019-08-26 Impact factor: 13.751

10 in total

Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.

Review 1. Roles of the NKG2D immunoreceptor and its ligands.

2. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity.

3. Distinct mechanisms of tumor resistance to NK killing: of mice and men.

4. Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.

5. Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection.

6. Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors.

Review 7. NKG2D ligands in tumor immunity.

8. Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype.

Review 9. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin.

Review 10. Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.

1. Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.

Review 2. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

3. Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

4. Control of Tumor Initiation by NKG2D Naturally Expressed on Ovarian Cancer Cells.

Review 5. Past, Current, and Future of Immunotherapies for Prostate Cancer.

6. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.

Review 7. Leveraging NKG2D Ligands in Immuno-Oncology.

8. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Review 9. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.

10. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC⁺ tumors respond to PD1/PD-L1 blockade therapy.